Abstract: Disclosed is a method for purifying Human interleukin-5 (IL-5) a single chromatographic step. After removing cells from a cell culture expressing human interleukin-5, IL-5 is purified by first adjusting the culture supernatant to the calculated pI value of mature IL-5 (pI=7.44) and then passing the conditioned supernatant through tandem linked anion- and cation-exchange columns. The resulting pass-through fraction contains the IL-5 and is devoid of all other contaminating proteins. An optional hydrophobic-interaction chromatography step is disclosed for positive selection of IL-5 and in order to concentrate the preparation. Pure IL-5 was recovered with a high overall yield (>90%), was N-glycosylated and was entirely homodimeric.
Abstract: Disclosed are recombinant, synthetically and otherwise biologically produced novel proteins and polypeptides which are encoded by the DNA sequence for HSV-2 glycoprotein G (gG) or fragments of said gG sequence particularly by the unique sequence for gG or portions of said unique sequence. The unique sequence proteins and polypeptides are serologically active, can be produced easily and safely at low cost, are useful as diagnostic reagents for HSV-2 and as vaccines against HSV-2. Further disclosed are serological assays based on such unique sequence gG proteins and polypeptides that diagnose the presence of herpes simplex virus type 2 (HSV-2) specific antibodies and can differentiate between HSV-2 and herpes simplex virus type 1 (HSV-1) specific antibodies. Such assays are useful to diagnose genital infections, to detect for exposure to HSV-2 and to screen pregnant women to protect newborns from neonatal HSV-2 infection.
Type:
Grant
Filed:
November 21, 1995
Date of Patent:
September 9, 1997
Assignee:
Chiron Diagnostics Corporation
Inventors:
Deborah Lynn Parkes, Stephen Ralph Coates
Abstract: Disclosed are recombinant, synthetically and otherwise biologically produced novel proteins and polypeptides which are encoded by the DNA sequence for HSV-2 glycoprotein G (gG) or fragments of said gG sequence, particularly by the unique sequence for gG or portions of said unique sequence. The unique sequence proteins and polypeptides are serologically active, can be produced easily and safely at low cost, are useful as diagnostic reagents for HSV-2 and as vaccines against HSV-2. Further disclosed are serological assays based on such unique sequence gG proteins and polypeptides that diagnose the presence of herpes simplex virus type 2 (HSV-2) specific antibodies and can differentiate between HSV-2 and herpes simplex virus type 1 (HSV-1) specific antibodies. Such assays are useful to diagnose genital infections, to detect for exposure to HSV-2 and to screen pregnant women to protect newborns from neonatal HSV-2 infection.
Type:
Grant
Filed:
May 25, 1995
Date of Patent:
August 12, 1997
Assignee:
CIBA Corning Diagnostics Corporation
Inventors:
Deborah Lynn Parkes, Stephen Ralph Coates
Abstract: The present invention relates to purified and isolated citrus blight, antigens and antibodies thereto leaf proteins which are specific indicators of the presence of citrus blight. The isolated and purified citrus blight leaf proteins are extracted from citrus blighted leaves and have a molecular weight of about 10,000 to about 30,00 daltons.
Type:
Grant
Filed:
January 6, 1995
Date of Patent:
July 22, 1997
Assignee:
The United States of America as represented by the Secretary of Agriculture
Abstract: Human Monoclonal antibodies effective for the diagnosis and treatment of Herpes Simplex Virus 1 and 2 have been prepared from a cell line obtained by fusing a xenogeneic hybridoma designated SPAZ 4 with spleen cells of a patient immune to Herpes Simplex Virus.
Type:
Grant
Filed:
September 13, 1994
Date of Patent:
July 8, 1997
Inventors:
Elisabeth Harfeldt, Philip Lake, Barbara Nottage, Lars G. Ostberg